A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

Inclusion criteria

• Participate in the study voluntarily, sign the informed consent form.
• Subjects were able to provide primary or metastatic cancer samples.
• At least one measurable lesion (RECIST version 1.1).
• ECOG 0~1.
• With adequate organ functions.
• Expected survival time ≥ 12 weeks.

Exclusion criteria

• With untreated brain metastasis or active central nervous system tumor metastases.
• Imaging shows that the tumor invades large blood vessels or has unclear boundaries with blood vessels.
• Patients with other malignant tumors in the past or at the same time.
• Patients with clinical symptoms, uncontrolled, or moderate or above pleural effusion, pericardial effusion, or peritoneal effusion.
• Patients with a history of interstitial pneumonia or interstitial lung disease or non-infectious pneumonia requiring steroid treatment.
• With poorly controlled or severe cardiovascular disease.
• Bleeding events of NCI-CTCAE v5.0 grade ≥ 2 occurred within 1 month before the first medication.
• Subjects who had a serious infection within 1 month before the first medication.
• History of immunodeficiency.
• Known allergy to any component of the SHR-7782 product.
• According to the researcher's judgment, there are other factors that may affect the research results or cause the research to be terminated midway.